Advertisement

Abbott to buy Galapagos arthritis-drug rights for up to $1.35 billion

Abbott Laboratories agreed to pay Galapagos as much as $1.35 billion for rights to an experimental rheumatoid arthritis drug that would compete with a Pfizer pill.

Read More
Tags:

Comments

Loading Comments Loading comments...
Advertisement